Investor Information
News
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
You are leaving SMMTTX.com
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.
To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.